6533b857fe1ef96bd12b5025

RESEARCH PRODUCT

Vomilenine Reductase — a novel Enzyme catalyzing a crucial Step in the Biosynthesis of the Therapeutically applied Antiarrhythmic Alkaloid Ajmaline

Joachim StöckigtGerald Von SchumannShujuan Gao

subject

TryptamineRauvolfiaStereochemistryClinical BiochemistryPharmaceutical ScienceReductaseBiochemistryCatalysisRauwolfiaIndole Alkaloidschemistry.chemical_compoundRauvolfia serpentinaDrug DiscoverymedicineSecologanin Tryptamine AlkaloidsMolecular BiologyCells CulturedAjmalineChromatographyMolecular StructurebiologyOrganic ChemistryTemperatureHydrogen-Ion Concentrationbiology.organism_classificationSecologanin Tryptamine AlkaloidsAjmalinechemistryBiochemistryVomilenineMolecular MedicineSecologaninOxidoreductasesAnti-Arrhythmia AgentsNADPmedicine.drug

description

Delineation of the biochemical pathway leading to the antiarrhythmic Rauvolfia alkaloid ajmaline has been an important target in biosynthetic research for many years. The biosynthetic sequence starting with tryptamine and the monoterpene secologanin consists of about 10 different steps. Most of the participating enzymes have been detected and characterized previously, except those catalyzing the reduction of the intermediate vomilenine. A novel NADPH-dependent enzyme that reduces the intermediate has been isolated from Rauvolfia serpentina cell suspension cultures. Vomilenine reductase (M(r )43 kDa, temp opt 30 degrees C, pH opt 5.7-6.2), saturates the indolenine double bond of vomilenine with stereospecific formation of 2beta(R)-1,2-dihydrovomilenine. The described detection, enrichment and properties of the reductase not only closes a gap in ajmaline biosynthesis but is also a prerequisite for overexpressing the protein heterologously for final clarification of its molecular properties.

https://doi.org/10.1016/s0968-0896(01)00435-7